AllAnalyst Report
logoMorningstarJuly 29, 2020

BioNTech SE: Raising Our BioNTech FVE on COVID-19 Vaccine Profits, but Long-Term Vaccine Outlook Remains Hazy

Symbols
BNTX
Sector(s)
Healthcare
Rating
Premium
Current Price
$106.50
Fair Value
Premium
Economic Moat
Premium
Stewardship
Premium
Summary

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and small-molecule immunomodulators. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab, and does not yet have any commercialized medicines.

Premium
Subscribe to Yahoo Finance Premium for full access
Read the latest independent research including analyst forecasts, ratings on the US economy, and more. Get individual company and overall sector level recommendations.
Try Premium FREE